The Business Journals11h
Months after acquisition, Watertown RNA biotech lays off workers
Months after acquiring Cambridge-based ReNAgade Therapeutics, Watertown’s Orna Therapeutics has made layoffs as it focuses ...
Morningstar13h
AN2 Therapeutics to Meet With FDA on Epetraborole Development Path
AN2 Therapeutics said it was planning to meet with the U.S. Food and Drug Administration to discuss a development path for epetraborole, a treatment of non-tuberculous mycobacterial lung disease. The ...
GlobalData on MSN14h
Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment
Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...
H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024
Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Key highlights Lundbeck's total revenue grew by +13% CER[1] (+10% DKK) to DKK 16,463 milli ...
Business Insider23h
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
Begin your TipRanks Premium journey today. Longboard Pharmaceuticals (LBPH) Company Description: Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel ...